ABSTRACT
Background The COVID-19 pandemic adversely disrupted global health service delivery. We aimed to assess impact of the pandemic on same-day HIV diagnosis/ART initiation, six-months non-retention and initial virologic non-suppression (VnS) among individuals starting antiretroviral therapy (ART) in Kenya.
Methods Individual-level longitudinal service delivery data were analysed. Random sampling of individuals aged >15 years starting ART between April 2018 – March 2021 was done. Date of ART initiation was stratified into pre-COVID-19 (April 2018 – March 2019 and April 2019 – March 2020) and COVID-19 (April 2020 – March 2021) periods. Mixed effects generalised linear, survival and logistic regression models were used to determine the effect of COVID-19 pandemic on same-day HIV diagnosis/ART initiation, six-months non-retention and VnS, respectively.
Results Of 7,046 individuals sampled, 35.5%, 36.0% and 28.4% started ART during April 2018 – March 2019, April 2019 – March 2020 and April 2020 – March 2021, respectively. Compared to the pre-COVID-19 period, the COVID-19 period had higher same-day HIV diagnosis/ART initiation (adjusted risk ratio [95% CI]: 1.09 [1.04–1.13], p<0.001) and lower six-months non-retention (adjusted hazard ratio [95% CI]: 0.66 [0.58–0.74], p<0.001). Of those sampled, 3,296 (46.8%) had a viral load test done at a median 6.2 (IQR, 5.3–7.3) months after ART initiation. Compared to the pre-COVID-19 period, there was no significant difference in VnS during the COVID-19 period (adjusted odds ratio [95% CI]: 0.79 [95%% CI: 0.52–1.20], p=0.264).
Conclusions In the short term, the COVID-19 pandemic did not have an adverse impact on HIV care and treatment outcomes in Kenya. Timely, strategic and sustained COVID-19 response may have played a critical role in mitigating adverse effects of the pandemic and point towards maturity, versatility and resilience of the HIV program in Kenya. Continued monitoring to assess long-term impact of the COVID-19 pandemic on HIV care and treatment program in Kenya is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This analysis is based on data from the national data warehouse (NDW) which is supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of mechanism ID 18214. At the time of the analysis, the NDW was under the technical management of the Palladium group with oversight from the National HIV/AIDS Strategic Information and Evaluation technical working group. Views expressed in this publication are those of the authors and not necessarily those of PEPFAR, CDC or the Palladium group.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective analysis was part of a National HIV program evaluation exercise. Ethics approval to waive need for informed consenting was obtained from the Africa Medical Research Foundation (AMREF) Ethics Scientific Review Committee, Kenya (AMREF-ESRC P716/2019). The analysis was reviewed in accordance with the U.S. Centers for Disease Control and Prevention (CDC) human research protection procedures and was determined to not meet the definition of research as defined in 45CFR46.102. All the data used in the analysis were fully anonymized. Thus, authors did not have access to information that could identify individual participants during or after data collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
De-identified data used in this analysis is available from the National EMR data warehouse in Kenya managed by the Ministry of Health.
